EMR
Emerson Electric Co.
EMR has lower modeled downside risk, despite its lower overall score.
VRT
Vertiv Holdings Co
VRT has the edge over EMR overall, supported by stronger valuation and stronger modeled upside.
EMR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
EMR's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
VRT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
VRT's revenue, profitability, cash flow and balance sheet are all currently strong.
EMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $49.84 | -70% |
| Fair | 22x | $107 | -36% |
| Forward | 23x | $167 | — |
| Expensive | 33x | $160 | -4.2% |
| Current | 35x | $167 | — |
Historical ranges are pointers, not guarantees.
EMR's PE is in its expensive range at 35x. If earnings grow as analysts expect, today's price would be 23x next year's earnings, in its fair range.
VRT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $210 | — |
| Current | 39x | $210 | — |
| Cheap | 58x | $308 | +47% |
| Fair | 72x | $383 | +83% |
| Expensive | 88x | $472 | +125% |
Historical ranges are pointers, not guarantees.
VRT has the edge over EMR in the historical PE scenario, which offers more potential upside but is not a forecast.
EMR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for EMR, with profitability improving.
VRT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for VRT, with profitability improving.
EMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.30 | +53% |
| Q3 2026 | $4.78 | +18% |
| Q2 2026 | $4.57 | -1.7% |
| Q1 2026 | $4.33 | +3.6% |
| Q4 2025 | $4.09 | -2.4% |
| Q3 2025 | $4.04 | +18% |
| Q2 2025 | $4.65 | +56% |
| Q1 2025 | $4.18 | -78% |
| Q4 2024 | $4.19 | -78% |
EMR's earnings per share have fallen from their peak: $4.78 over the past year, against $22.92 in late 2023.
VRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.14 | +71% |
| Q3 2026 | $5.35 | +102% |
| Q2 2026 | $4.42 | +111% |
| Q1 2026 | $3.98 | +131% |
| Q4 2025 | $3.41 | +166% |
| Q3 2025 | $2.65 | +75% |
| Q2 2025 | $2.09 | +62% |
| Q1 2025 | $1.72 | +64% |
| Q4 2024 | $1.28 | +7.6% |
VRT has the edge over EMR on earnings, with more consistent year-over-year improvement.
EMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.2B | +7.1% |
| Q2 2026 | $4.9B | +7% |
| Q1 2026 | $4.6B | +2.9% |
| Q4 2025 | $4.3B | +4.1% |
| Q3 2025 | $4.9B | +5.1% |
| Q2 2025 | $4.6B | +3.9% |
| Q1 2025 | $4.4B | +1.3% |
| Q4 2024 | $4.2B | +1.4% |
EMR's revenue has grown year over year for 12 quarters in a row: $5.2B last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2.9 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +3.2 points |
| Q4 2025 | 18% | -0.7 points |
| Q3 2025 | 16% | +1.7 points |
| Q2 2025 | 16% | +5.7 points |
| Q1 2025 | 14% | -0.7 points |
| Q4 2024 | 19% | +15 points |
EMR's operating margin was 19% last quarter, up 2.9 points from the same quarter a year ago.
VRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.3B | +61% |
| Q2 2026 | $3.3B | +24% |
| Q1 2026 | $2.6B | +30% |
| Q4 2025 | $2.9B | +23% |
| Q3 2025 | $2.7B | +29% |
| Q2 2025 | $2.6B | +35% |
| Q1 2025 | $2B | +24% |
| Q4 2024 | $2.3B | +26% |
VRT has the edge over EMR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +3.5 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +2.3 points |
| Q4 2025 | 20% | +0.7 points |
| Q3 2025 | 19% | +1.4 points |
| Q2 2025 | 17% | -0.4 points |
| Q1 2025 | 14% | +1.9 points |
| Q4 2024 | 19% | +4.2 points |
VRT has the edge over EMR on profitability, with a higher operating margin.
EMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $917M | +8.9% |
| Q2 2026 | $1.3B | +35% |
| Q1 2026 | $694M | +351% |
| Q4 2025 | $602M | -13% |
| Q3 2025 | $842M | -8.1% |
| Q2 2025 | $977M | -2.1% |
| Q1 2025 | $154M | -77% |
| Q4 2024 | $694M | +105% |
EMR generated $3.5B in free cash flow over the past year, up 33% from the year before.
VRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $654.9M | +41% |
| Q2 2026 | $926.5M | +233% |
| Q1 2026 | $654.2M | +145% |
| Q4 2025 | $885.6M | +143% |
| Q3 2025 | $463.5M | +36% |
| Q2 2025 | $277.9M | -19% |
| Q1 2025 | $266.8M | +162% |
| Q4 2024 | $364.5M | +18% |
VRT has the edge over EMR on cash flow, with more consistent year-over-year improvement.
EMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +900K shares |
| 1 year | -0.8% | -4.7M shares |
| 3 years | -2.7% | -15.3M shares |
| 5 years | -6.6% | -39.8M shares |
| Available history | -8.5% | -52.1M shares |
EMR has the edge over VRT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $102M |
| Q2 2026 | $356M |
| Q1 2026 | $292M |
| Q4 2025 | $250M |
| Q3 2025 | $20M |
| Q2 2025 | $25M |
| Q1 2025 | $223M |
| Q4 2024 | $899M |
EMR spent $1B buying back its own shares over the past year, down 14% from the year before.
VRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -64.9K shares |
| 1 year | +0.4% | +1.8M shares |
| 3 years | +1.1% | +4.4M shares |
| 5 years | +10% | +36M shares |
| Available history | +63% | +152M shares |
VRT has 393M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $599.9M |
EMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 1.1x | Healthy |
EMR's net debt is about 2.1 years of its operating earnings (EBITDA), down from 2.6 years a year ago.
VRT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.8x | Very low |
| Q4 2024 | 1.0x | Healthy |
VRT has the edge over EMR on leverage, with a lower net debt burden relative to earnings.
EMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.0 | Neutral |
| Stochastic | 74.4 | Neutral |
EMR's weekly RSI is 64 (neutral) and its Stochastic is 74 (neutral).
VRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 26.4 | Neutral |
VRT's weekly RSI is 43 (neutral) and its Stochastic is 26 (neutral).
EMR PE vs Industrials Sector
| Metric | EMR | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 24x | 45% above |
| PE % | 89 | 58 | 31 pts above |
EMR has the edge over VRT on valuation relative to its sector.
VRT PE vs Industrials Sector
| Metric | VRT | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 24x | 63% above |
| PE % | 3 | 58 | 55 pts below |
VRT is trading at 39x earnings, a 63% premium to the Industrials sector's median of 24x.
EMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $162.4 | 2.8% above |
| 20 week MA | $155.2 | 7.6% above |
| 50 week MA | $146.6 | 14% above |
| 100 week MA | $135.9 | 23% above |
| 200 week MA | $117.9 | 42% above |
EMR has the edge over VRT on trend strength, trading above more of its moving averages.
VRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $221.8 | 5.5% below |
| 20 week MA | $254.4 | 18% below |
| 50 week MA | $253.9 | 17% below |
| 100 week MA | $189.1 | 11% above |
| 200 week MA | $123.5 | 70% above |
VRT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 70% above its 200-week average.
EMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.5 | $80.0 | +4.5% |
| 2021 | $80.0 | $91.3 | +14% |
| 2022 | $91.3 | $95.5 | +4.7% |
| 2023 | $95.5 | $97.3 | +1.9% |
| 2024 | $97.3 | $125.7 | +29% |
| 2025 | $125.7 | $135.7 | +8% |
| 2026 YTD | $135.7 | $166.9 | +23% |
EMR has finished every year since 2020 higher, and it's up 23% so far in 2026.
VRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.9 | $18.9 | +73% |
| 2021 | $18.9 | $24.9 | +31% |
| 2022 | $24.9 | $12.8 | -48% |
| 2023 | $12.8 | $48.0 | +275% |
| 2024 | $48.0 | $115.1 | +140% |
| 2025 | $115.1 | $167.6 | +46% |
| 2026 YTD | $167.6 | $209.6 | +25% |
VRT has the edge over EMR on returns for 2026, with the stronger performance.